Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.
AffiliationClinical Oncology Unit, University of Bradford, Bradford BD7 1DP, UK.
MetadataShow full item record
AbstractThe O(6)-alkylguanine-DNA alkyltransferase inactivator O(6)-benzylguanine was administered to BALB/c mice either alone or before exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea to study the role of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase in the protection of the testis against anti-cancer O(6)-alkylating agents. Exposure of the mice to 1, 3-bis(2-chloroethyl)-1-nitrosourea or O(6)-benzylguanine alone did not produce any marked testicular toxicity at the times studied. Testicular O(6)-alkylguanine-DNA alkyltransferase concentrations were assayed between 0 and 240 min after O(6)-benzylguanine treatment and were shown to be > 95% depleted 15 min after treatment with O(6)-benzylguanine and remained at > 95% at all the times assayed. Histological examination, the reduction in testicular mass and the induction of spermatogenic cell apoptosis showed that this depletion significantly potentiated 1, 3-bis(2-chloroethyl)-1-nitrosourea-induced testicular damage after treatment. Major histological damage was apparent 42 days after treatment, demonstrating that the stem spermatogonia were significantly affected by the combination. These results demonstrate that O(6)-alkylguanine-DNA alkyltransferase plays a significant role in protecting the spermatogenic cells from damage caused by DNA alkylation and indicate that the observed toxicity may result from damage to stem spermatogonia.
CitationRole of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents. 2000, 119 (2):339-46 J. Reprod. Fertil.
JournalJournal of Reproduction and Fertility
- Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
- Authors: Hansen RJ, Nagasubramanian R, Delaney SM, Cherian MM, Lin S, Kogan SC, Dolan ME
- Issue date: 2005 Dec
- Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
- Authors: Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, Szabo SK, Fu P, Gilliam AC, Gerson SL, Remick SC, Cooper KD
- Issue date: 2012 May
- Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
- Authors: Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C
- Issue date: 1996 Sep 1
- Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
- Authors: Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME
- Issue date: 2000 Oct 1
- O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells.
- Authors: Westerhof GR, Down JD, Blokland I, Wood M, Boudewijn A, Watson AJ, McGown AT, Ploemacher RE, Margison GP
- Issue date: 2001 May